Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Friday, June 1, 2007

A recent Euro-pean study examined the contribution of the metabolic syndrome to the risk of developing venous throm-boembolism (VTE). This case?control study was designed to investigate the presence of the metabolic syndrome, defined according to guidelines of the National Cholesterol Education Program, in high-risk patients with objectively confirmed recurrent VTE who had had at least 1 unprovoked event of deep vein thrombosis or pulmonary embolism. A total of 116 VTE patients and 129 controls were enrolled. The prevalence of the metabolic syndrome was statistically significantly higher in VTE patients (40/116; 35%) than in controls (26/129; 20%; P = .012). The adjusted odds ratio of the metabolic syndrome for VTE was 2.2 after adjustment for established thrombosis risk factors, sex, and age. Individuals with the metabolic syndrome (n = 66) had significantly higher levels of high-sensitivity C-reactive protein, fibrinogen, and factor VIII activity, compared with patients without metabolic syndrome.

Latest Articles
OTC medications can have serious side effects in children if they are not carefully administered.
Patients with asthma can now access Spiriva Respimat with a prescription at pharmacies across the country.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
Latest Issues